- Home
- CHEK vs QNTM Comparison
CHEK vs QNTM Comparison
Compare CHEK & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEK
- QNTM
- Stock Information
- Founded
- CHEK 2004
- QNTM 1998
- Country
- CHEK Israel
- QNTM Canada
- Employees
- CHEK N/A
- QNTM N/A
- Industry
- CHEK Medical Electronics
- QNTM
- Sector
- CHEK Health Care
- QNTM
- Exchange
- CHEK Nasdaq
- QNTM NYSE
- Market Cap
- CHEK 9.0M
- QNTM 9.1M
- IPO Year
- CHEK 2015
- QNTM N/A
- Fundamental
- Price
- CHEK $1.30
- QNTM $3.42
- Analyst Decision
- CHEK
- QNTM
- Analyst Count
- CHEK 0
- QNTM 0
- Target Price
- CHEK N/A
- QNTM N/A
- AVG Volume (30 Days)
- CHEK 3.7M
- QNTM 223.5K
- Earning Date
- CHEK 02-14-2025
- QNTM 01-28-2025
- Dividend Yield
- CHEK N/A
- QNTM N/A
- EPS Growth
- CHEK N/A
- QNTM N/A
- EPS
- CHEK N/A
- QNTM N/A
- Revenue
- CHEK N/A
- QNTM N/A
- Revenue This Year
- CHEK N/A
- QNTM N/A
- Revenue Next Year
- CHEK N/A
- QNTM N/A
- P/E Ratio
- CHEK N/A
- QNTM N/A
- Revenue Growth
- CHEK N/A
- QNTM N/A
- 52 Week Low
- CHEK $0.56
- QNTM $2.70
- 52 Week High
- CHEK $3.45
- QNTM $70.85
- Technical
- Relative Strength Index (RSI)
- CHEK 52.13
- QNTM 41.28
- Support Level
- CHEK $1.25
- QNTM $3.20
- Resistance Level
- CHEK $1.69
- QNTM $3.55
- Average True Range (ATR)
- CHEK 0.28
- QNTM 0.43
- MACD
- CHEK -0.02
- QNTM -0.00
- Stochastic Oscillator
- CHEK 36.25
- QNTM 14.97
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.